ADVAGRAF 5 mg, extended-release capsule 30 capsules, CIP 3400949501045
Active ingredients: Tacrolimus, Tacrolimus hydrate
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule30 capsules, CIP 3400949501045orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ADVAGRAF 5 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) PVC unidose(s) PVDC suremballée(s)/surpochée(s) aluminium de 1 gélule(s) Distributeur parallèle : BB Farma)
- Marketing authorisation holder
- ASTELLAS PHARMA EUROPE (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 7 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61727612CIP74950104CIP133400949501045Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TACROLIMUSgélule | 5 mg · une gélule | FT |
| TACROLIMUS MONOHYDRATÉgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.